There's still the GE Healthcare collaboration, but this outcome has drastically changed my outlook of this company. I sold half before and will monitor the GE Healthcare developments, but likely to get out earlier.
So, my gathering is they spent ages previously after finding a 'better' lead and have only realised during human testing that the pharmacodynamics of this iterarion are different. "This is not seen with other i-bodies" - direct quote from their presentation. So, they didn't bother to test this pharmacology 101 aspect for AD-214 until now? Seems amateurish to me.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)